JOINT Corp
For the period ended Dec 31, 2024. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 14, 2025
JYNT$6.83+2.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows for the
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(8,529,843) | $(9,752,197) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation and amortization | 4,722,137 | 8,582,203 |
| Net loss on disposition or impairment (non-cash portion) | 10,454,609 | 2,632,604 |
| Net franchise fees recognized upon termination of franchise agreements | (239,335) | (217,827) |
| Deferred income taxes | (55,556) | 10,896,504 |
| Provision for credit losses on accounts receivable | 220,893 | — |
| Stock based compensation expense | 1,679,005 | 1,737,682 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,645,078) | 192,348 |
| Prepaid expenses and other current assets | 160,082 | (341,478) |
| Deferred franchise costs | 499,285 | 355,952 |
| Deposits and other assets | 8,827 | 1,492 |
| Accounts payable | 68,258 | (1,381,836) |
| Accrued expenses | 4,609,759 | 793,679 |
| Payroll liabilities | 2,398,765 | 1,455,234 |
| Operating lease liabilities | (3,796,648) | (107,735) |
| Upfront regional developer fees | (421,213) | (598,778) |
| Deferred revenue | (597,489) | 301,095 |
| Other liabilities | (121,408) | 128,647 |
| Net cash provided by operating activities | 9,415,050 | 14,677,589 |
| Cash flows from investing activities: | ||
| Acquisition of CA clinics | — | (1,188,765) |
| Proceeds from sale of clinics | 554,100 | — |
| Purchase of property and equipment | (1,185,647) | (4,999,070) |
| Net cash used in investing activities | (631,547) | (6,187,835) |
| Cash flows from financing activities: | ||
| Payments of finance lease obligation | (25,484) | (24,432) |
| Purchases of treasury stock under employee stock plans | (9,583) | (3,833) |
| Proceeds from exercise of stock options | 33,708 | 202,386 |
| Repayment of debt under the Credit Agreement | (2,000,000) | — |
| Net cash (used in) provided by financing activities | (2,001,359) | 174,121 |
| Increase in cash | 6,782,144 | 8,663,875 |
| Cash, cash equivalents and restricted cash, beginning of period | 19,214,292 | 10,550,417 |
| Cash, cash equivalents and restricted cash, end of period | $25,996,436 | $19,214,292 |
| December 31, 2024 | December 31, 2023 | |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $25,051,355 | $18,153,609 |
| Restricted cash | 945,081 | 1,060,683 |
| $25,996,436 | $19,214,292 | |
Supplemental cash flow disclosures:
The following table represents supplemental cash flow disclosures and non-cash investing and financing activities:
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net cash paid for: | ||
| Interest | $69,445 | $173,062 |
| Income taxes | $610,492 | $569,765 |
| Non-cash investing and financing activity: | ||
| Unpaid purchases of property and equipment | $124,699 | $140,055 |
| Stock option exercise receivable | $896,766 | $— |
| Non-cash investment in acquisition of franchised clinics | $— | $28,997 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.